Phase II, Double blind, Randomized, Placebo controlled, Parallel group, Trial to Explore the Potential Anti-dyskinetic Properties of CPL500036 (PDE10A inhibitor) in Patients with Parkinson's Disease Suffering from Levodopa Induced Dyskinesia

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 12 Jul 2024

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs CPL 500036 (Primary)
Indications Parkinson's disease
Focus Therapeutic Use
Sponsors Celon Pharma

Most Recent Events

09 Jul 2024 According to Celon Pharma media release, Phase 2 results expected to be reported in 4Q 2024.
15 May 2024 Planned End Date changed from 1 Jul 2024 to 1 Dec 2024.
15 May 2024 Planned primary completion date changed from 1 Jun 2024 to 1 Nov 2024.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight